STAT3 and Cachexia: Agents such as ruxolitinib and INCB018424 have shown preclinical efficacy in mitigating cachexia symptoms by suppressing STAT3 phosphorylation, normalizing cytokine/adipokine profiles, and reducing tissue wasting (54, 57, 157, 158).